Mode
Text Size
Log in / Sign up
N/A N=60 Randomized Treatment

XprESS Eustachian Tube Dilation Study

Eustachian Tube Dysfunction

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcome: Primary: Change From Baseline in Mean Overall ETDQ-7 Scores — -2.9; -0.6 units on a scale — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
XprESS (Device); Control (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Entellus Medical, Inc.
Primary completion
Mar 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Mean Overall ETDQ-7 Scores
-2.9; -0.6 <0.0001 sig
PRIMARY
Complication Rate
0; 0
SECONDARY
Technical Success Rate
100
SECONDARY
Revision Rate
SECONDARY
Mean Change in Overall ETDQ-7 Score
-2.5 <0.0001 sig
SECONDARY
Mean Change in Overall ETDQ-7 Score
-2.5 <0.0001 sig
SECONDARY
Mean Change in Overall ETDQ-7 Score
-2.5 <0.0001 sig
SECONDARY
Mean Change in Overall ETDQ-7 Score
-2.5 <0.0001 sig

Summary

Study to assess the safety and efficacy of the XprESS device for transnasal Eustachian tube dilation.

Eligibility Criteria

Inclusion Criteria

  • ≥18 years old
  • Have been diagnosed with symptoms of chronic Eustachian tube dysfunction for no less than 12 months prior to enrollment
  • Have an overall ETDQ-7 score ≥3.0
  • Have record of failed medical management for Eustachian tube dysfunction

Exclusion Criteria

  • Require concomitant procedures at the time of the study enrollment or procedure
  • Have patulous Eustachian tube
  • Have ear tubes in place or perforation of the tympanic membrane
  • Have evidence of internal carotid artery dehiscence
  • Be pregnant at the time of enrollment
  • Be currently participating in other drug or device studies
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02391584). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search